Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa

• Published in: Vaccine Vol. 30; pp. A79 - A85
• Main Authors: Tapia, Milagritos D, Armah, George, Breiman, Robert F, Dallas, Michael J, Lewis, Kristen D.C, Sow, Samba O, Rivers, Stephen B, Levine, Myron M, Laserson, Kayla F, Feikin, Daniel R, Victor, John C, Ciarlet, Max, Neuzil, Kathleen M, Steele, A. Duncan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 27.04.2012
• Subjects: Administration, Oral; Africa South of the Sahara - epidemiology; Allergy and Immunology; clinical trials; disease severity; Double-Blind Method; etiology; Female; G genotype; Gastroenteritis; Gastroenteritis - epidemiology; Gastroenteritis - pathology; Gastroenteritis - prevention & control; genotype; HIV infections; Human immunodeficiency virus; Humans; Infant; infants; Male; mortality; P genotype; Placebos - administration & dosage; public health; Rotavirus; Rotavirus Infections - epidemiology; Rotavirus Infections - pathology; Rotavirus Infections - prevention & control; Rotavirus Vaccines - administration & dosage; Rotavirus Vaccines - immunology; Severity of Illness Index; Vaccination - methods; Vaccine efficacy; vaccines; Vaccines, Attenuated - administration & dosage; Vaccines, Attenuated - immunology; Kenya; Mali; Ghana; Africa South of the Sahara; G genotype; Rotavirus; Gastroenteritis; P genotype; Vaccine efficacy
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2012.01.022

Highlights ► We report post hoc subgroup analyses on secondary endpoints of public health importance of the PRV efficacy study in Africa. ► VE against rotavirus GE of any severity was 49% through the first year of life and 31% through the complete follow-up period. ► VE against severe-gastroenteritis of any etiology was 22% through the first year of life and 11% through the complete follow-up period. ► VE against severe rotavirus GE caused by both homologous and heterologous strains was observed.